FDA To Decide On Encysive's Thelin

The Food and Drug Administration will decide in late July whether to approve Encysive Pharmaceuticals Inc.'s (ENCY) high blood pressure treatment Thelin. Shares of the biopharmaceutical firm jumped $1.96 to close at $7.01.